Long Read Sequencing Market Updates

Global Long Read Sequencing Market size was valued at USD 595.81 million in 2023 and is poised to grow from USD 779.92 million in 2024 to USD 6723.02 million by 2032, growing at a CAGR of 30.9% during the forecast period (2025-2032).

The primary operational players have used a number of measures to increase their market presence because this is a market that is expanding quickly. As an example, Illumina will introduce its powerful Illumina Complete Long Read Prep, Human assay for human whole-genome sequencing in March 2023. 'Pacific Biosciences of California, Inc. (PacBio) (United States) ', 'Oxford Nanopore Technologies plc (United Kingdom) ', 'Illumina, Inc. (United States) ', 'BGI Genomics Co., Ltd. (China) ', '10x Genomics, Inc. (United States) ', 'Agilent Technologies, Inc. (United States) ', 'Thermo Fisher Scientific Inc. (United States) ', 'QIAGEN N.V. (Germany) ', 'Takara Bio Inc. (Japan) ', 'Danaher Corporation (United States) ', 'Novogene Co., Ltd. (China) ', 'New England Biolabs, Inc. (United States) ', 'Element Biosciences, Inc. (United States) ', 'Revvity, Inc. (United States) ', 'Eurofins Scientific SE (Luxembourg) ', 'Bio-Rad Laboratories, Inc. (United States) ', 'PerkinElmer, Inc. (United States) ', 'Roche Holding AG (Switzerland) ', 'Merck KGaA (Germany) ', 'Bio-Techne Corporation (United States)'

Next-generation sequencing (NGS) technologies are widely adopted in research applications across various fields, including genomics, transcriptomics, and epigenomics. Long read sequencing provides additional insights into genome assembly, gene expression, and DNA modification patterns, driving its adoption in NGS-based research.

Increasing Adoption of Long Read Sequencing: Long read sequencing technologies are gaining significant traction in the market due to their ability to provide more comprehensive and accurate genomic information compared to short read sequencing. This trend is driven by the increasing demand for applications such as genome assembly, structural variant analysis, and transcriptomics.

North America held a 50.85% share of the global market in 2022 as a result of the existence of significant players like Pacific Biosciences, the accessibility of a strong informatics network, and established laws for the approval and marketing of goods and services for genetic testing. Furthermore, it is projected that the growing academic and clinical use of genomic methods in the US will speed up market expansion there.